+ data and comment +, page-26

re: pbt2 share price rose 158pc after correction It's interesting, given your theory of Packer involvement, that PBT managed to get simultaneous country-wide publicity several days after the company's announcement of what might otherwise have been thought interesting, but really rather humdrum animal results, fell on deaf ears. The article Stolwyck quoted above also appeared on the front page of The West Australian this morning.

I don't mean in any way to run PBT down. However, another Melbourne-based company (with which I declare an interest), Solagran, announced extremely encouraging HUMAN trial results for its drug, Ropren, in relation to Alzheimer's a little under a year ago to barely any fanfare. And Ropren is a drug which is just about ready for commercialisation.

I guess there is always an element of 'the timing needing to be right' about any announcement, but one can't help wondering as to the extent of media manipulation.

Not that I am complaining if it draws investment dollars back to the biotech sector. We'll all benefit in the long run, if that occurs!